AlphAIalphai — Financial news for AI agents
stocktitan.netSEP 12 min read$HNGE

Hinge Health (HNGE) trust flags potential stock sale, follows Insight funds’ multimillion-dollar exits

Hinge Health (HNGE) filed a notice under Rule 144 for potential sales of Class A shares by the Jeffrey Lieberman 2012 Family Trust, a 10% stockholder. Recent sales by Insight Venture Partners funds included blocks of shares totaling millions. Raymond James & Associates is the broker. HNGE has 62.47 million Class A shares outstanding.

Original reporting
stocktitan.net
Published Sep 1, 2026, 9:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 2, 2026, 1:54 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$HNGE
Bearish
high confidence
Mentioned
$HNGE
Relevance
7/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$HNGEBearishMed
01

Why it matters

The disclosed sales total over $110M, representing a notable portion of float and could depress the share price in the short term.

02

Market read

Primary insider sale filing likely to create short-term selling pressure on HNGE.

03

What to watch

Potential that the sales are part of a broader secondary market transaction unrelated to company fundamentals.

Relevance 7/10Novelty 8/10Timing: published Sep 1 2026

Background

Form 144 filings disclose planned sales of restricted shares by insiders, providing transparency on upcoming share supply.

Company-level read

Ticker impact

$HNGEBearishHigh confidence
Context

Form 144 filing reveals a 10% shareholder and Insight Venture Partners funds selling over $110M of Hinge Health Class A shares in June‑August 2026.

Expected impact

Potential short-term downside as market absorbs new shares.

Evidence & confidence

The disclosed sales represent a material amount relative to float and are recent, indicating near‑term selling pressure.

Market effects

Sector

May signal increased insider selling in the digital health sector, prompting peers to watch for similar activity.

Regional

U.S. market focus; limited regional effect.

Global

Low global relevance beyond investors tracking Hinge Health.

Counterpoint

What could challenge this read

If the sales are strategic liquidity events, the stock could rebound once the market digests the supply shock.

Key entities

  • 10% shareholder
    Jeffrey Lieberman 2012 Family Trust

    Holder of a 10% stake filing a Rule 144 notice.

  • Venture capital firm
    Insight Venture Partners

    Multiple funds selling large blocks of HNGE shares.

Read at source← All news

Related articles

AUG 28
$HNGEHighAI 8/10

Could Hinge Health (HNGE) Stock Win as Digital Healthcare Expands Beyond MSK Care?

Hinge Health (NYSE:HNGE) raised its 2026 revenue guidance to $856M-$860M, up from $822.16M consensus. Q2 2026 revenue grew 53% YoY to $213M, with non-GAAP operating income doubling to $62M. The company announced a $105M acquisition of Cylinder Health and expanded its share repurchase program by $300M. Analysts RBC and Truist raised price targets to $110 and $112, respectively, citing strong growth and platform expansion.

finance.yahoo.com3 min
AUG 19
$HNGEMedAI 8/10

HNGE Stock Surges Nearly 90% YTD: Can Its Growth Story Continue?

Hinge Health (HNGE) stock has risen 90% YTD, outperforming industry and S&P 500. Q2 revenue grew 53% YoY to $213M, with 2026 guidance raised to $856-$860M. AI and automation improved margins, while new care programs expand market reach. Analysts project 2026 EPS of $2.50 and 2027 EPS of $3.29. Growth is driven by member yield, AI efficiency, and new care offerings, but execution risks remain.

zacks.com3 min
AUG 15
$HNGEMed

Jim Cramer says one stock hitting new highs is still a screaming buy

Jim Cramer reiterated a triple buy call on Hinge Health (HNGE) on “Mad Money” Aug. 11. The stock hit a new all-time high of $93.13 on Aug. 10 and is up about 85.83% YTD, per Yahoo Finance. Hinge reported Q2 2026 revenue of $213 million (+53% YoY), free cash flow of $99.6 million, and raised FY guidance to $856-$860 million. It also agreed to a $105 million cash acquisition (Cylinder Health) to expand into GI care.

yahoo.com6 min
AUG 12
$HNGEMed

Hinge Health (HNGE) Just Bought Its Way Into A New Market, So Now What?

Hinge Health (NASDAQ:HNGE) reported Q2 revenue of $213 million, up 53% year over year, above guidance of $200 million to $202 million. Gross margin rose to 87% and operating income to $62 million. The company said it used $105 million cash to acquire Cylinder Health for gastrointestinal care, while also expanding its migraine offering. It raised FY revenue guidance to $856 million to $860 million and authorized a $300 million buyback.

insidermonkey.com7 min
AUG 5
$HNGEHighAI 9/10

Why is Hinge Health stock surging today?

Hinge Health (HNGE) shares rose 11.6% after the company reported Q2 2026 revenue of $212.8M (+53% YoY) and non-GAAP diluted EPS of $0.59 vs $0.13 consensus. Free cash flow exceeded $100M. Hinge raised FY2026 revenue guidance to $818M-$824M and Q3 guidance to $223M-$225M, and agreed to buy Cylinder Health for $105M cash. Analysts lifted price targets.

investing.com4 min